Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Haiyan Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1371-3734; OpenAlex author ID A5048151775. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper

Papers 10

  1. Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib. Co-author DOI 10.1186/s12943-024-01965-5↗
  2. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12885-021-08375-6↗
  3. A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer. Co-author DOI 10.21037/tcr-20-3478↗
  4. RNA-binding protein Musashi2 regulates Hippo signaling via SAV1 and MOB1 in pancreatic cancer. Co-author DOI 10.1007/s12032-020-01384-8↗
  5. Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression. Co-author DOI 10.1186/s13046-019-1489-0↗
  6. MST1 Suppresses Pancreatic Cancer Progression via ROS-Induced Pyroptosis. Co-author DOI 10.1158/1541-7786.mcr-18-0910↗
  7. Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Co-author DOI 10.1038/s41598-017-03153-6↗
  8. Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients. Co-author DOI 10.18632/oncotarget.12447↗
  9. Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.7663↗
  10. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. Co-author DOI 10.1007/s00432-015-1953-y↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiujie Cui · 6 shared papers, 2019–2024 · strength 0.74
  2. Feng Jiao · 6 shared papers, 2016–2021 · strength 0.62
  3. Ming Quan · 4 shared papers, 2019–2024 · strength 0.50
  4. Tiebo Mao · 3 shared papers, 2021–2024 · strength 0.42
  5. Jiong Hu · 4 shared papers, 2015–2021 · strength 0.34
  6. Liwei Wang · 3 shared papers, 2019–2020 · strength 0.32
  7. Liwei Wang · 2 shared papers, 2021 · strength 0.24
  8. Liwei Wang · 4 shared papers, 2015–2017 · strength 0.24
  9. Lei Wang · 1 shared paper, 2024 · strength 0.18
  10. Xiaofei Zhang · 1 shared paper, 2024 · strength 0.18
  11. Weiyu Ge · 1 shared paper, 2024 · strength 0.18
  12. Ting Han · 2 shared papers, 2016–2021 · strength 0.18
  13. Junjie Hang · 2 shared papers, 2016–2017 · strength 0.13
  14. Yiyi Liang · 1 shared paper, 2021 · strength 0.13
  15. Jiayu Yao · 1 shared paper, 2021 · strength 0.13
  16. Hai Xia Hu · 2 shared papers, 2016 · strength 0.12
  17. Lei Wang · 2 shared papers, 2016 · strength 0.12
  18. Weiyi Huang · 2 shared papers, 2015–2017 · strength 0.12
  19. Yu Wang · 1 shared paper, 2021 · strength 0.11
  20. Zhiqin Chen · 1 shared paper, 2020 · strength 0.10
  21. Yong Gao · 1 shared paper, 2019 · strength 0.10
  22. Peng Xue · 1 shared paper, 2017 · strength 0.07
  23. Meng Zhuo · 1 shared paper, 2016 · strength 0.06
  24. Ning Li · 1 shared paper, 2015 · strength 0.05
  25. Peng Xue · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.